{"doi":"10.1093/ibd/izaf316","title":"Hidden Clues in the Epithelial Brush Border: A New Prognostic Marker for Pediatric Crohn’s Disease","abstract":"Identifying dependable biomarkers in Crohn’s disease has remained an enduring challenge. Increasingly over the last couple of decades, clinicians have relied on inflammation-based indicators such as ESR, CRP, fecal calprotectin, and leukocyte-derived proteins to detect flares and assess treatment response.1 These tools are useful for monitoring active disease but offer limited insight into the downstream clinical course of a patient with newly diagnosed Crohn’s disease (eg, develop strictures or fistulas or require surgery). This gap has motivated extensive efforts to define molecular, serologic, microbial, and other markers capable of forecasting progression. Multiple studies have advanced promising candidates, and large national initiatives such as the Danish PREDICT program underscore the commitment to solving this problem.2 Yet new markers have not entered routine clinical practice as most show modest effect sizes or lack reproducibility outside of discovery cohorts. Even ambitious efforts like the recent PROFILE study,3 which evaluated a whole-blood transcriptional risk signature, ultimately failed to generate a clinically actionable test. One of PROFILE’s most important observations was that patients receiving early, aggressive therapy did remarkably well, a finding that underscores the need for reliable prognostic indicators that would justify top-down treatment at diagnosis. Thus, the unmet need persists; we still lack biomarkers that are reproducible, mechanistically grounded, and practical for widespread use.","journal":"Inflammatory Bowel Diseases","year":2025,"id":586786,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9554,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":106969,"name":"Matthew A. Ciorba","orcid":"0000-0002-7656-0982","position":1,"is_corresponding":false},{"id":12648,"name":"Chao Li","orcid":"0000-0001-6106-468X","position":0,"is_corresponding":true}],"reference_count":13,"raw_metadata":null,"created_at":"2026-07-19T02:59:32.191237Z","pmid":"41428333","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}